Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
about
Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signallingRole of sorafenib in the treatment of advanced hepatocellular carcinoma: An updateAmbulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatmentSynergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor RapamycinSelective use of sorafenib in the treatment of thyroid cancerHistone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancerClinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumorCopy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in MelanomaRole of receptor tyrosine kinases in gastric cancer: new targets for a selective therapyEarly sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary studyThe study of a novel sorafenib derivative HLC-080 as an antitumor agentActivated p53 with Histone Deacetylase Inhibitor Enhances L-Fucose-Mediated Drug Delivery through Induction of Fucosyltransferase 8 Expression in Hepatocellular Carcinoma CellsRenal cell cancer: overview of the current therapeutic landscape.Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors.Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2More sound cancer therapy biomarker development with active noise control.Vascular endothelial growth factor as an anti-angiogenic target for cancer therapySorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.Diffusion MRI in early cancer therapeutic response assessment.Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis.Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits.A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience.Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlatesPhase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.Diffusion-weighted MRI for assessment of early cancer treatment response.(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.Sorafenib cardiotoxicity increases mortality after myocardial infarction.Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosisCorrelation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenibSorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemiaPhase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.
P2860
Q24314807-EB9C426D-770C-41B6-B26F-E26B69C915D9Q24619987-1EE23B50-22A6-496C-BE8C-9B8CC9CE6918Q24657761-3CEC0575-D98F-4653-9ECA-10B00C8F93CCQ24811525-D6EB4035-6A15-46C9-98AC-1DED3CF36A75Q26752891-563AC00B-8003-4921-B861-6FEE3152D14BQ26777453-69C2E488-7053-4FD4-B16D-39013BC2DCE0Q27005824-D7C3D145-3BF7-41DE-BF8B-A12D6B466624Q27853202-8E1ADC7D-C77E-445D-9F62-0E856BF4C95CQ28242840-C42CC103-CF3D-41E2-BC52-40762291975FQ28482219-D130D4CF-AEAD-4010-9CC9-B96F4FD3B5A5Q28540521-F2958979-4E97-405F-BB4A-2B0A17FFFAF6Q28555059-700D79A4-AF73-4BCD-81F5-95F336E24BE3Q30248354-0DA38855-47BA-495C-B638-8914632C3582Q30317831-C2E91BDA-30EB-46BB-A082-322A802AEC8AQ30439284-1F6047CA-1EF8-46EA-94A2-3DFC0480DEB1Q30442454-19FCBDFA-ABC8-4195-BCC3-F5D8343BBCD6Q30455612-C30C7960-F6AF-4FA3-B2B4-BABFE7790FC7Q30587082-9EAC4415-C4AA-4064-9553-8DE049510E3CQ31037179-69A9CC28-C4F0-4522-B181-E7D03E779C49Q33166002-AE90F07E-AE18-4191-8CD0-B21CE08AB3FDQ33259095-14CB45BA-28A9-4D64-8CA8-BF6B770F7901Q33400837-033F4E57-C1E0-4EC4-BF4B-CE087BA63D71Q33403207-310F8CB2-9E19-40AC-9311-459E4CD79367Q33404411-5F8B87F6-9176-4AC6-BAA6-D91665E9C9BDQ33406591-27F8F5A3-3CCD-4875-A01C-BF7D382E0870Q33408279-F3143798-E1CA-4C3B-BB57-27E6262315ACQ33411001-6E54A0F6-99A7-4AFE-9575-7FE2DE25FDDCQ33577870-E366F4C9-55E9-42DE-AC65-8452B3D25E16Q33588005-2F6E65F9-1CB8-44A4-9560-A28FE588D6E6Q33590458-83FF8767-48E7-4EFD-AABD-70C6013E7CF5Q33620083-6CBC3CA9-AF96-41C4-BC70-BC1C6A05A24CQ33680292-82870C68-17B2-40A1-AD19-700C3850AB84Q33681995-50B621A2-3B5D-415A-B185-C9CF036FB84BQ33728406-B961388A-FBB4-4552-9EB2-9C4142AD73FEQ33745283-2B0D44FE-F2A8-4E2C-B09A-66100C92335DQ33758211-6B863DA7-56E6-4ECF-BADA-40579C6BA149Q33780701-309F1398-CE79-4DF0-A909-CB6652D3F805Q33900952-C6B76EDB-407F-4005-B12D-36696E0CD08FQ33943277-4210E094-8B9B-4F9B-9AE9-2E9C3DBF4C6EQ33990908-D081EBCC-05F8-4B9F-8F14-2CB87E29878C
P2860
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Phase I clinical and pharmacok ...... anced refractory solid tumors.
@en
type
label
Phase I clinical and pharmacok ...... anced refractory solid tumors.
@en
prefLabel
Phase I clinical and pharmacok ...... anced refractory solid tumors.
@en
P2093
P356
P1476
Phase I clinical and pharmacok ...... anced refractory solid tumors.
@en
P2093
Ahmad Awada
Brian Schwartz
Claus G Haase
Dimitris Voliotis
Dirk Strumberg
Erich Brendel
Heike Richly
Markus Faghih
Max E Scheulen
Mitra Tewes
P304
P356
10.1200/JCO.2005.06.124
P407
P577
2004-12-21T00:00:00Z